SureTrader Nadex Advertisement
Home > Boards > US OTC > Biotechs >

Neurotrope Inc. (NTRP)

NTRP RSS Feed
Add NTRP Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, Bob Stocks, runncoach, PatrickBateman, kld2
Search This Board: 
Last Post: 2/26/2017 11:19:19 AM - Followers: 47 - Board type: Free - Posts Today: 3

NTRPD Security Details
Share Structure


Market Value1 $45,774,160 a/o Jan 18, 2017
Authorized Shares 12,500,000 a/o Jan 12, 2017
Outstanding Shares 6,781,357 a/o Jan 12, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 1,627,372 a/o Jan 12, 2017

COMPANY PRESENTATION

http://neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/HomePage-Forms/Neurotrope%20%20100516.pdf

Top line Phase 2 study results expected to be released in April 2017The Company has also raised an additional $4.3 million in a final closing of its private placement for a total amount of $24.5 million

 

NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Neurotrope, Inc. (otcqb:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today announced that it has initiated dosing in the final patient in its randomized, double-blinded, placebo-controlled, Phase 2 study in moderate to severe Alzheimer's disease patients.  The primary endpoint of the trial is the Severe Impairment Battery (SIB) and the secondary endpoints are the Mini Mental State Exam (MMSE), Activity of Daily Living (ADL) and Neuropsychiatric Inventory scale (NPI).  Top line results from the study are expected to be announced in April 2017.  Patients meeting the MMSE enrollment criteria score of 4-15 were enrolled in the study.  Two doses of bryostatin, 20ug and 40ug, vs. placebo for 12 weeks are being tested.  A total of 148 patients were enrolled into the study. 

The Company also announced that it has raised an additional $4.3 million in a final closing of its private placement in addition to the approximately $20.2 million raised and previously announced in a press release on Friday, November 18, 2016.

"Completion of enrollment in this study marks a significant milestone for Neurotrope, as well as the Alzheimer's community, as we take another step toward advancing what we believe could be the first potential new treatment for people with Alzheimer's disease in more than 15 years, and we believe would be the first one targeting causes of the symptoms, lost synaptic networks, and not just providing transient symptomatic relief," said Dr. Daniel Alkon, MD, Neurotrope's President and Chief Scientific Officer.  "Other companies targeting this disease are enrolling mildly impaired patients. We targeted the more severe patient population because of our experience with severe patients through our compassionate use studies. Those studies suggested reversal of some of the manifestations of the disease."

"Bryostatin's multi-modal mechanism of action not only targets the neuronal deficits of AD but also synaptic deficits.  This combined mechanism of action through PKC epsilon activation gave the Company the confidence to commit to these trials in moderate to severe patients," said Dr. Susanne Wilke, PhD., the Company's Chief Executive Officer.  "We believe that we may have a breakthrough in Alzheimer's disease and other neurological disorders. With the recently completed financing, we believe that we are in a strong position to negotiate terms with pharmaceutical partners."

Josh Silverman, Chairman of the Company, added, "We are pleased with the investor response to our new management team and the excitement surrounding our upcoming clinical data.  We raised more money than anticipated and plan on investing our capital efficiently in our continuing effort to increase shareholder value while making a difference in treating neurological disorders."

Further details may be found in the Company's Form 8-K filing with the Securities and Exchange Commission (SEC).

The securities to be sold in the private placement will not have been registered under the Securities Act of 1933, as amended, or state securities laws as of the time of issuance and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements.  Neurotrope has agreed to file one or more registration statements with the SEC registering the resale of the shares of common stock underlying the warrants purchased in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Neurotrope         

Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a focus on developing a novel therapy for the treatment of moderately severe to severe Alzheimer's disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes and a by bryostatin, a natural product, which in mouse AD models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.  

Neurotrope is also conducting preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease, two rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome.  Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.

Neurotrope has exclusively licensed technology from Cognitive Research Enterprises (formerly named the Blanchette Rockefeller Neurosciences Institute) for Alzheimer's disease therapeutics and Fragile X Syndrome and has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C disease. 

Trial details 
NTRP Security Details
 
 
 
 
 
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTRP
Current Price
Volume:
Bid Ask Day's Range
SureTrader
NTRP News: Current Report Filing (8-k) 02/24/2017 05:03:56 PM
NTRP News: Statement of Changes in Beneficial Ownership (4) 02/22/2017 05:03:45 PM
NTRP News: Initial Statement of Beneficial Ownership (3) 02/22/2017 05:02:51 PM
NTRP News: Current Report Filing (8-k) 02/22/2017 05:02:26 PM
NTRP News: Notice of Effectiveness (effect) 02/15/2017 06:01:35 AM
PostSubject
#893  Sticky Note Major New Seeking Alpha article: SF Wolf 02/17/17 03:21:30 PM
#710  Sticky Note Why I will be watching but not investing XenaLives 02/14/17 10:51:33 AM
#679  Sticky Note February 13 conference...includes results from compassionate use patients runncoach 02/13/17 03:30:18 PM
#1259   If you Google "the role of oxidative stress XenaLives 02/26/17 11:19:19 AM
#1257   ------------ "It is accepted fact that the underlying cause F1ash 02/26/17 12:45:08 AM
#1256   Free radial causes a lot of problems and Maple tree 02/25/17 10:44:37 PM
#1255   It is accepted fact that the underlying cause blu_1 02/25/17 09:30:35 PM
#1254   "More than $200 million dollars has gone into F1ash 02/25/17 09:16:56 PM
#1253   Can you show us where that's the case runncoach 02/25/17 08:58:02 PM
#1252   Proximity to clogged highways could increase risk of XenaLives 02/25/17 08:40:28 PM
#1251   I think the question is - what XenaLives 02/25/17 08:35:21 PM
#1250   blu, I think you should qualify your statement: SF Wolf 02/25/17 08:08:02 PM
#1249   I am as well. Fascinating by the psychology kld2 02/25/17 07:39:23 PM
#1248   bryostatin restores the synaptic networks which is the drbio45 02/25/17 07:15:09 PM
#1247   Curious what Monday will bring...a modest increase of bUrRpPPP! 02/25/17 07:06:43 PM
#1246   The problem with Neurotrope is that is doesn't blu_1 02/25/17 06:13:07 PM
#1245   It would be wise to raise before data. kld2 02/25/17 11:12:17 AM
#1243   Neurotrope has ownership in some of the outstanding BioBull1 02/25/17 10:48:27 AM
#1242   This A/S increase is not news. Warrant lawdawg05 02/25/17 10:00:03 AM
#1241   8k was released at 5 pm yesterday. Shareholders BioBull1 02/25/17 07:42:47 AM
#1240   I did not attend. I assume (yep F1ash 02/24/17 06:53:06 PM
#1239   Just curious: anyone go to the special meeting kld2 02/24/17 06:37:03 PM
#1238   Your doing a great of job keeping on NotRichYet2 02/24/17 01:06:33 PM
#1237   It always pays to scrutinize PRs carefully and F1ash 02/24/17 12:10:05 PM
#1236   Agree - all combined make those pullbacks somewhat NotRichYet2 02/24/17 11:41:06 AM
#1235   That and specific results for compassionate use patients runncoach 02/24/17 11:33:48 AM
#1234   That new release was IMO the main trigger NotRichYet2 02/24/17 11:29:25 AM
#1233   F1ash, here is the press release. SF Wolf 02/24/17 10:56:25 AM
#1232   Some DD I've been effortiing. Alcon has a patent F1ash 02/24/17 10:44:31 AM
#1231   Insightful Tweet: SF Wolf 02/24/17 10:14:12 AM
#1230   Thx Wolf runncoach 02/24/17 10:01:13 AM
#1229   Neurotrope hopes to succeed with new tack in SF Wolf 02/24/17 09:05:03 AM
#1228   It is not ME that I am referring BioBull1 02/24/17 08:24:44 AM
#1227   Thanks BioBull1, I don't think they will release Theburg 02/24/17 06:16:23 AM
#1226   I don't know if BioBull1 is right or kld2 02/24/17 04:47:15 AM
#1225   No complaint and so far so good. It Maple tree 02/23/17 10:49:19 PM
#1224   You've seen it already. It's insignificant and completely normal. FlowtraderES 02/23/17 09:23:29 PM
#1223   I think most understand the difference between a/s runncoach 02/23/17 08:27:06 PM
#1222   Waiting to see the reaction of most when BioBull1 02/23/17 08:05:34 PM
#1221   Did you not see my response earlier? BioBull1 02/23/17 07:59:50 PM
#1220   I definitely don't know what will happen between runncoach 02/23/17 03:24:20 PM
#1218   I knew it would hit 20 before results. runncoach 02/23/17 03:12:50 PM
#1217   Did tap the 20 dollar marker briefly today. NotRichYet2 02/23/17 03:03:06 PM
#1216   Thanks GentleGiant123, I appreciate the response. Theburg 02/23/17 02:50:43 PM
#1215   not trying to be sarcastic GentleGiant123 02/23/17 02:26:55 PM
#1214   I'm trying to get a feel for what Theburg 02/23/17 02:24:55 PM
#1213   There was a hard sell off yesterday and Selett 02/23/17 02:00:17 PM
#1212   As of last week they said 'any day Selett 02/23/17 01:58:54 PM
#1211   Sure been fun runncoach 02/23/17 01:49:25 PM
#1210   Anyone have a recent response from the company lawdawg05 02/23/17 01:29:24 PM
#1209   I'm more nervous with the rising prices than GentleGiant123 02/23/17 01:22:48 PM
#1208   Yes, in that case, I would agree with SF Wolf 02/23/17 11:54:38 AM
#1207   I agree. But just saying that I don't CND 02/23/17 11:44:51 AM
PostSubject